BORA - UiB

Bergen Open Research Archive

Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy

Bergen Open Research Archive

Show simple item record

dc.contributor.author Zubac, Dragomir eng
dc.contributor.author Wentzel-Larsen, Tore eng
dc.contributor.author Seidal, Tomas eng
dc.contributor.author Bostad, Leif eng
dc.date.accessioned 2011-04-08T06:35:30Z
dc.date.available 2011-04-08T06:35:30Z
dc.date.issued 2010-12-03 eng
dc.identifier.citation BMC Urology 10:20 en_US
dc.identifier.issn 1471-2490 eng
dc.identifier.uri http://hdl.handle.net/1956/4635
dc.description.abstract Background To examine the expression of type 1 plasminogen inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC), and its possible association with microvessel density (MVD), the expression of thrombospondin-1 (TSP-1), nuclear grade, tumour stage, continuously coded tumour size (CCTS) and to assess the value of PAI as a prognostic marker in 162 patients with CCRCC treated with radical nephrectomy. Methods A total of 172 consecutive patients with CCRCC treated with radical nephrectomy were enrolled in the study. The expression of PAI-1, TSP-1 and factor VIII were analysed on formalin-fixed, paraffin-embedded tissues without knowledge of the clinical outcome. Ten cases, where PAI-1 immunohistochemistry was not possible due to technical problems and lack of material, were excluded. Sixty-nine patients (43%) died of RCC, while 47 patients (29%) died of other diseases. Median follow-up was 13.8 years for the surviving 46 patients (28%). Results Nine percent of the tumours showed PAI-1 positivity. High expression of PAI-1 was significantly inversely correlated with TSP-1 (p = 0.046) and directly with advanced stage (p = 0.008), high NG (3+4) (p = 0.002), tumour size (p = 0.011), microvessel density (p = 0.049) and disease progression (p = 0.002). In univariate analysis PAI-1 was a significant prognosticator of cancer-specific survival (CSS) (p < 0.001). Multivariate analysis revealed that TNM stage (p < 0.001), PAI-1 (p = 0.020), TSP-1 (p < 0.001) and MVD (p = 0.007) were independent predictors of CSS. Conclusions PAI-1 was found to be an independently significant prognosticator of CSS and a promoter of tumour angiogenesis, aggressiveness and progression in CCRCC. en_US
dc.publisher BioMed Central eng
dc.rights Attribution CC BY eng
dc.rights.uri http://creativecommons.org/licenses/by/2.0 eng
dc.title Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy eng
dc.type Journal article eng
dc.type Peer reviewed eng
dc.subject.nsi VDP::Medical disciplines: 700 eng
dc.rights.holder Copyright 2010 Zubac et al; licensee BioMed Central Ltd.
dc.rights.holder Zubac et al. eng
dc.type.version publishedVersion eng
bora.peerreviewed Peer reviewed eng
bora.cristinID 1047840 eng
bibo.doi http://dx.doi.org/10.1186/1471-2490-10-20 eng
dc.identifier.cristinID 1047840 eng
dc.identifier.doi http://dx.doi.org/10.1186/1471-2490-10-20


Files in this item

 
 

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY Except where otherwise noted, this item's license is described as Attribution CC BY

Search BORA


Browse

My Account